Anemia of chronic disease is the most common type of anemia among hospitalized patients, yet it behaves nothing like the iron-deficiency anemia most people think of when they hear the word “anemia.” Rather than a shortage of iron in the body, it involves iron being locked away where the body cannot use it, a consequence of the immune system’s response to ongoing illness. The condition shows up alongside infections, autoimmune disorders, kidney disease, and cancer, and it tends to carry worse clinical outcomes than straightforward iron deficiency. Understanding how it works matters because the usual fix for anemia, taking iron supplements, can be useless or even counterproductive here.
What Happens Inside the Body
The central player in anemia of chronic disease is a small hormone called hepcidin, produced mainly by the liver. During chronic inflammation, immune signaling molecules, particularly one called interleukin-6, ramp up hepcidin production dramatically.1PubMed Central. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin Hepcidin’s job is to control ferroportin, the only known gateway that moves iron out of cells and into the bloodstream. When hepcidin levels spike, ferroportin gets broken down, and iron becomes trapped inside the cells that store or recycle it.2Blood. Hepcidin and iron regulation, 10 years later Iron absorbed from food in the gut, iron held in liver storage cells, and iron recovered from old red blood cells by immune cells called macrophages all stay locked in place instead of entering circulation.
The result is a paradox: the body’s total iron stores may be normal or even elevated, but the iron available for making new red blood cells is critically low. This iron-restricted state leads directly to reduced red blood cell production.3Blood. Distinct roles for hepcidin and interleukin-6 in the recovery from anemia in mice injected with heat-killed Brucella abortus
Iron trapping is only part of the story. Inflammatory molecules also suppress erythropoietin, the hormone produced mainly by the kidneys that tells bone marrow to make red blood cells. Cytokines like interleukin-1 and tumor necrosis factor-alpha directly inhibit the gene that produces erythropoietin, meaning the marrow gets a weaker signal to ramp up red cell production even as the body needs more of them.4Journal of Interferon & Cytokine Research. Proinflammatory Cytokines Lowering Erythropoietin Production On top of that, these same inflammatory signals can interfere with the bone marrow’s ability to respond to whatever erythropoietin is present, blunting red cell production from both ends.5PubMed Central. Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis
There is also a third hit. Red blood cells themselves become casualties of the inflammatory environment. Under inflammatory conditions, oxidative stress damages circulating red blood cells, triggering a self-destruction process in which the cell’s membrane flips certain molecules to its outer surface. This acts as a “eat me” signal for patrolling macrophages, which gobble up the damaged cells before they reach the end of their normal lifespan.6PubMed Central. Influence of Inflammation on Red Blood Cell Lifespan in Peritoneal Dialysis Patients So the body is simultaneously making fewer red blood cells and destroying existing ones faster than normal.
Why Your Body Does This on Purpose
The iron-trapping mechanism sounds harmful, and it is, but it did not evolve by accident. Iron is essential to nearly every living organism, including the bacteria and other pathogens that cause infections. By pulling iron out of circulation during an infection, the immune system starves invading microbes of a nutrient they desperately need. Researchers call this strategy “nutritional immunity,” a defense mechanism animals evolved to limit iron availability to pathogens.7PubMed Central. Innate Nutritional Immunity
This defense works well during a short-lived infection. The problem arises when the inflammatory signal never shuts off. In chronic conditions like rheumatoid arthritis, Crohn’s disease, or cancer, the immune system keeps hepcidin elevated week after week, month after month. What was once a clever antimicrobial tactic becomes a sustained assault on the body’s own red blood cell supply. The anemia that results is essentially collateral damage from an immune system stuck in combat mode.
Who Gets It and How Common It Is
Anemia of chronic disease can develop alongside virtually any condition that produces ongoing inflammation. A hospital-based study of 482 anemic patients found that about 46% had anemia of chronic disease, compared to 30% with iron deficiency anemia, making it the more common diagnosis in that setting.8European Journal of Cardiovascular Medicine. Prevalence and Clinical Outcomes of Anemia of Chronic Disease Versus Iron Deficiency Anemia in Hospitalized Patients: A Cross-Sectional Analysis A separate study at a tertiary care hospital found that roughly 31% of anemic patients met criteria for the condition, with diabetes, high blood pressure, and chronic kidney disease as the most common underlying illnesses. Age made a substantial difference: rates were about four times higher in patients over 80 than in young adults.9medRxiv. Prevalence of Anemia of Chronic Disease/Inflammation at a Tertiary Care Hospital in North India
In rheumatic diseases like rheumatoid arthritis and lupus, the prevalence of anemia tracks with disease severity. Patients in a flare are more likely to be anemic than those in remission, because the inflammatory burden driving hepcidin production rises and falls with disease activity.10Nature. Anaemia in inflammatory rheumatic diseases Cancer-related anemia is another major category, characterized by low circulating iron and low transferrin saturation despite adequate iron stores, the hallmark of an inflammatory iron-trapping pattern.11PubMed Central. Cancer Related Anemia: An Integrated Multitarget Approach and Lifestyle Interventions
Most cases are mild, which can be misleading. In the tertiary care study, about two-thirds of patients had mild anemia, but roughly a sixth had severe anemia.12medRxiv. Prevalence of Anemia of Chronic Disease/Inflammation at a Tertiary Care Hospital in North India Even mild cases carry clinical weight. The cross-sectional study of hospitalized patients found that those with anemia of chronic disease spent an average of about two days longer in the hospital, were readmitted within 30 days at nearly double the rate, and had in-hospital mortality more than double that of patients with iron deficiency anemia.13European Journal of Cardiovascular Medicine. Prevalence and Clinical Outcomes of Anemia of Chronic Disease Versus Iron Deficiency Anemia in Hospitalized Patients: A Cross-Sectional Analysis That difference likely reflects the severity of the underlying diseases driving the anemia, but it underscores that treating this type of anemia as a harmless lab finding is a mistake.
Why It Is Easy to Confuse with Iron Deficiency
On a standard blood count, anemia of chronic disease and iron deficiency anemia can look nearly identical. Both can produce low hemoglobin. Both can sometimes show smaller-than-normal red blood cells. The key difference lies in iron studies, but even those can mislead. Serum ferritin, the most commonly ordered marker of iron stores, is an acute-phase reactant. That means inflammation pushes ferritin levels up regardless of actual iron reserves. A patient with true iron deficiency who also has an active inflammatory disease might have a “normal” ferritin level that masks an underlying deficiency. Meanwhile, a patient with anemia of chronic disease will typically show normal or high ferritin because their iron is locked away in storage cells, not absent from the body.
This overlap matters clinically because the two conditions can coexist. A patient with Crohn’s disease, for instance, might have anemia of chronic disease from gut inflammation and iron deficiency anemia from chronic intestinal bleeding, all at once. Research has examined several biomarkers to help tease the two apart. Total iron binding capacity (a measure of transferrin, the blood’s iron-transport protein) has shown strong discriminating power, along with soluble transferrin receptor, a marker that rises when cells are truly iron-starved at the tissue level, and is less affected by inflammation than ferritin.14American Journal of Clinical Pathology. Discriminating Between Iron Deficiency Anemia and Anemia of Chronic Disease Using Traditional Indices of Iron Status vs Transferrin Receptor Concentration
A calculated index combining soluble transferrin receptor with ferritin (the sTfR-ferritin index) has proven particularly useful for detecting hidden iron deficiency within a background of chronic inflammation. In patients with inflammatory bowel disease, a high sTfR-ferritin index had sensitivity and specificity both above 90% for identifying true iron deficiency.15PubMed Central. Soluble transferrin receptor-ferritin index in the evaluation of anemia in inflammatory bowel disease: a case-control study Studies in rheumatoid arthritis have confirmed this index outperforms soluble transferrin receptor alone for spotting iron deficiency coexisting with chronic disease anemia.16PubMed. Soluble transferrin receptor and transferrin receptor-ferritin index in iron deficiency anemia and anemia in rheumatoid arthritis
A newer marker, reticulocyte hemoglobin content, measures how much hemoglobin is inside the youngest red blood cells freshly released from bone marrow. Because reticulocytes only live a day or two in the blood, this marker gives a real-time snapshot of whether iron was available during the most recent round of red cell production. Studies in surgical patients found it could discriminate iron deficiency anemia with good accuracy.17PubMed Central. Reticulocyte hemoglobin content: a new frontier in iron deficiency diagnostics for major surgical patients This is the kind of test that is increasingly being added to automated blood analyzers, making it more accessible in routine practice.
Why Iron Supplements Often Do Not Help
If you have straightforward iron deficiency, taking iron supplements makes obvious sense: the body is short on iron, so you add more. With anemia of chronic disease, the problem is not a lack of iron in the body but an inability to use the iron that is already there. The hepcidin-driven blockade means that oral iron absorbed from the gut will largely get trapped in the same way as dietary iron. And intravenous iron, which bypasses the gut entirely, runs into a different version of the same problem.
Animal research comparing oral and intravenous iron in inflammatory anemia found that neither approach improved hemoglobin levels in pure anemia of chronic disease. Intravenous iron in particular ended up trapped in liver and spleen macrophages, pushed hepcidin levels even higher, and increased the inflammatory cytokine interleukin-6.18PubMed Central. Comparative analysis of oral and intravenous iron therapy in rat models of inflammatory anemia and iron deficiency In the mixed condition, where chronic disease anemia and iron deficiency overlap, both oral and intravenous iron did improve hemoglobin, which is why distinguishing “pure” anemia of chronic disease from the mixed form has real treatment implications.
In inflammatory bowel disease, where the two types frequently coexist, oral iron supplementation is widely used but can be poorly tolerated and less effective during active inflammation. Intravenous iron bypasses the gut absorption barrier, which is particularly relevant when the intestinal lining is itself inflamed and unable to absorb nutrients properly.19PubMed Central. Comparing the Efficacy of Intravenous Versus Oral Iron Supplementation for Anemic Patients With Inflammatory Bowel Disease: A Meta-Analysis The practical takeaway is that iron therapy can help the iron-deficient component of the anemia, but it cannot overcome the inflammatory component. For that, you need to address the underlying disease.
Treating the Underlying Disease Versus Treating the Anemia Directly
The most effective treatment for anemia of chronic disease is controlling the inflammation that causes it. When a rheumatoid arthritis patient achieves remission on immunosuppressive therapy, their anemia often improves without any direct anemia treatment. When an infection is cleared, hepcidin drops and iron flows back into circulation. This is why clinicians consider anemia of chronic disease a secondary problem: fix the primary illness, and the anemia follows.
But many chronic diseases cannot be switched off so neatly. Chronic kidney disease, advanced cancer, and persistent autoimmune conditions may never fully remit. For these patients, erythropoiesis-stimulating agents (ESAs) have been a mainstay. These drugs mimic the action of erythropoietin, the hormone the body is not producing enough of, and push the bone marrow to make more red blood cells. In chronic kidney disease, multiple ESAs have shown they can reduce the need for blood transfusions.20PubMed Central. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis
The catch is that ESAs come with serious risks. In cancer-related anemia, a meta-analysis found that ESAs reduced the need for blood transfusions by about a third but increased the risk of death during treatment by about 15% and the risk of blood clots by roughly 70%.21PubMed Central. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis In kidney disease, all major ESAs increased the odds of developing high blood pressure.22PubMed Central. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis These safety concerns have pushed guidelines toward using the lowest effective dose and targeting moderate hemoglobin levels rather than trying to normalize them completely. A review of the evidence found that while ESAs correct anemia and reduce transfusion needs in chronic kidney disease, the risks of cardiovascular events, tumor progression in cancer, and higher mortality have prompted a shift in treatment philosophy.23PubMed Central. Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease and Cancer-Related Anemia: A Narrative Review of Literature
Newer Drug Approaches
The limitations and risks of current treatments have driven research into drugs that target the specific mechanisms of anemia of chronic disease rather than just boosting red cell production. Two strategies have generated the most interest.
The first is a class of drugs called HIF-prolyl hydroxylase inhibitors (HIF-PHIs). These work by activating the body’s oxygen-sensing pathway, the same system that detects low oxygen at high altitude and triggers a natural increase in erythropoietin production. Unlike injected ESAs, which flood the body with high levels of the hormone, HIF-PHIs coax the body into producing more of its own erythropoietin in a more physiological pattern. They have an additional benefit directly relevant to anemia of chronic disease: they lower hepcidin levels and improve iron availability, potentially reducing the need for intravenous iron.24PubMed Central. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease Animal studies have confirmed that prolyl hydroxylase inhibitors can counteract inflammation-induced anemia by simultaneously boosting erythropoietin and driving down hepcidin.25PubMed. Pharmacological inhibition of prolyl hydroxylase protects against inflammation-induced anemia via efficient erythropoiesis and hepcidin downregulation Several of these drugs are already approved for kidney disease anemia in various countries, and their oral formulation is a practical advantage over injected ESAs.
The second strategy goes after hepcidin itself. Since hepcidin is the gatekeeper that locks iron inside cells, blocking it with an antibody could, in theory, release trapped iron and restore normal red blood cell production. Early-stage research has demonstrated the potential of fully human anti-hepcidin antibodies for treating iron-restricted anemias like those caused by inflammation, cancer, and chronic kidney disease.26PubMed Central. Anti-hepcidin therapy for iron-restricted anemias This approach is still in earlier clinical development than HIF-PHIs, but it represents a fundamentally different logic: instead of pushing the marrow harder to make red cells, it removes the iron blockade that is starving the marrow of raw materials.
Anemia in Older Adults and the Gray Zone
Aging complicates the picture considerably. Older adults are more likely to have chronic diseases, more likely to be inflamed at a low level even without a diagnosable condition (sometimes called “inflammaging”), and more likely to have anemia. Yet after extensive workup involving medical history, lab work, and sometimes bone marrow biopsy, anemia in older patients remains unexplained in up to 40% of cases.27PubMed Central. Unexplained anemia of aging: Etiology, health consequences, and diagnostic criteria The tertiary care hospital study noted that rates of anemia of chronic disease were about four times higher in people over 80 compared to those under 40.28medRxiv. Prevalence of Anemia of Chronic Disease/Inflammation at a Tertiary Care Hospital in North India
This “unexplained anemia of aging” likely represents a spectrum. Some of it is subclinical anemia of chronic disease driven by low-grade inflammation that does not show up as a clearly elevated inflammatory marker. Some of it may involve age-related changes in the bone marrow’s ability to respond to erythropoietin, or declining kidney function that is not yet severe enough to be classified as chronic kidney disease but is enough to dampen erythropoietin production. The diagnostic tools discussed earlier, like soluble transferrin receptor and reticulocyte hemoglobin, are particularly valuable in this population precisely because the standard markers can be ambiguous. A ferritin level that looks reassuringly “normal” in someone with chronic low-grade inflammation might be masking functional iron deficiency that would respond to treatment if identified.
For clinicians caring for older adults, the practical challenge is deciding when mild anemia is worth investigating aggressively versus when it reflects an underlying condition that is already being managed as well as it can be. There is no consensus threshold for intervention, and the risk-benefit calculation for treatments like ESAs shifts in a population already vulnerable to cardiovascular events and blood clots. For the patient, the most useful thing to know is that feeling fatigued, short of breath, or mentally foggy is not an inevitable consequence of getting older. If blood work shows anemia, it is worth figuring out which type it is, because the treatment path varies dramatically depending on the answer.
When Both Types of Anemia Overlap
Perhaps the trickiest clinical scenario is the patient who has anemia of chronic disease and true iron deficiency at the same time. This is not rare. Patients with inflammatory bowel disease lose iron through chronic intestinal bleeding while simultaneously having hepcidin-driven iron trapping from gut inflammation. Cancer patients may bleed from tumors and have inflammation-mediated anemia simultaneously. Rheumatoid arthritis patients taking nonsteroidal anti-inflammatory drugs may develop stomach ulcers that bleed, adding iron deficiency on top of their inflammatory anemia.
The animal model data mentioned earlier suggests this mixed state may actually respond better to iron therapy than pure anemia of chronic disease. In animals with combined chronic disease anemia and iron deficiency, both oral and intravenous iron improved hemoglobin, whereas in pure chronic disease anemia, neither worked.29PubMed Central. Comparative analysis of oral and intravenous iron therapy in rat models of inflammatory anemia and iron deficiency This is why correct diagnosis matters so much. Labeling a patient as “anemia of chronic disease” and withholding iron therapy when they actually have a mixed picture means missing the treatable component. The sTfR-ferritin index and reticulocyte hemoglobin content can help identify these patients, and clinicians who specialize in hematology or the underlying chronic condition tend to be more attuned to checking for both components than a general screening blood test would reveal.